GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

by Business Wire • 2024/09/23 • 0 Comments

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2024, and provided business updates since June. The 2024 half-year financial statements were subject to a limited review by the Company’s statutory au

← BLOG: Cornea could become the new glaucoma

One in Three Pro Football Players Think They Have CTE →

Post navigation